Hostname: page-component-cd9895bd7-gvvz8 Total loading time: 0 Render date: 2024-12-31T15:00:46.605Z Has data issue: false hasContentIssue false
  • English
  • Français

Altered dopaminergic function and negative symptoms in drug-free patients with schizophrenia

[123l]-iodobenzamide SPECT study

Published online by Cambridge University Press:  02 January 2018

Michael B. Knable ,
Michael F. Egan ,
Andreas Heinz ,
Julia Gorey ,
Kan Sam Lee ,
Richard Coppola  and
Daniel R. Weinberger
Michael B. Knable*
Affiliation:
Clinical Disorder Branch, Intramural Research Program, National Institute of Mental Health
Michael F. Egan
Affiliation:
Clinical Disorder Branch, Intramural Research Program, National Institute of Mental Health
Andreas Heinz
Affiliation:
Clinical Disorder Branch, Intramural Research Program, National Institute of Mental Health
Julia Gorey
Affiliation:
Clinical Disorder Branch, Intramural Research Program, National Institute of Mental Health
Kan Sam Lee
Affiliation:
Clinical Disorder Branch, Intramural Research Program, National Institute of Mental Health
Richard Coppola
Affiliation:
Clinical Disorder Branch, Intramural Research Program, National Institute of Mental Health
Daniel R. Weinberger
Affiliation:
Clinical Disorder Branch, Intramural Research Program, National Institute of Mental Health
*
M. B. Knable, Clinical Brain Disorders Branch, Intramural Research Program, National Institute of Mental Health, National Institutes of Health, 2700 Martin Luther King Jr Ave., S. E., Washington, DC 20032; Fax: 202-373-6214
Get access Rights & Permissions [Opens in a new window]

Abstract

Background

Previous in vivo studies of schizophrenia with dopamine D2 receptor radioligands have yielded contradictory results. No prior study has used multiple scans to examine within-subject clinical change.

Method

Twenty-one patients were studied with [1231]-iodobenzamide single photon emission computed tomography about two weeks after neuroleptic withdrawal. Thirteen of the 21 completed a second scan about four weeks after neuroleptic withdrawal. Sixteen controls were scanned for comparison.

Results

There was no significant difference between groups in [1231]-iodobenzamide uptake at either scanning session. No significant correlations with demographic variables (age, illness duration, drug-free period), or clinical ratings (positive and negative symptoms, movement disorder) were observed at either scanning session. There was a significant correlation between change in [1231]-iodobenzamide uptake and change in negative symptom ratings for the subjects who underwent two scans (r=0.72, P < 0.05)

Conclusions

Worsening of negative symptoms may be associated with increased availability of striatal D2 receptors, perhaps because of decreased concentrations of endogenous dopamine.

Type
Papers
Information
The British Journal of Psychiatry , Volume 171 , Issue 6 , December 1997 , pp. 574 - 577
Copyright
Copyright © 1997 The Royal College of Psychiatrists 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

American Psychiatric Association (1994) Diagnostic and Statistical Manual of Mental Disorders (4th edn) (DSM–IV) Washington. DC: APA.Google Scholar
Andreasen, N. C. (1984) Scale for the Assessment of Negative Symptoms. Iowa City, University of Iowa.Google Scholar
Bigelow, L. B. & Barthot, B. D. (1989) The psychiatric symptom assessment scale. Psychopharmacology Bulletin, 25, 168–179.Google ScholarPubMed
Bowers, M. B. (1974) Central dopamine turnover in schizophrenic syndromes. Archives of General Psychiatry, 31, 52–54.CrossRefGoogle ScholarPubMed
Farde, L., Wieseil, F. A., Stone-Elander, S., et al (1990) D2 dopamine receptors in neuroleptic-naïve schizophrenic patients. Archives of General Psychiatry, 47, 213–219.CrossRefGoogle ScholarPubMed
Innis, R. B., Malison, R. T., Al-Tikriti, M., et al (1992) Amphetamine-stimulated dopamine release competes in vivo for 1231 iodobenzamide binding to the D2 receptor in nonhuman primates. Synapse, 10, 177–184.CrossRefGoogle Scholar
Kapur, S. & Mann, J. J. (1992) Role of the dopaminergic system in depression. Biological Psychiatry, 32, 1–17.CrossRefGoogle ScholarPubMed
Knable, M. B., Jones, D. W. Coppola, R., et al (1995) Lateralized differences in iodine-123-iodobenzamide uptake in the basal ganglia in asymmetric Parkinson's disease. Journal of Nuclear Medicine, 36, 1216–1225.Google Scholar
Pilowsky, L. S., Costa, D. C., Ell, P. J., et al (1994) D2 dopamine receptor binding in the basal ganglia of antipsychotic-free schizophrenic patients. An 1231-iodobenzamide single photon emission computerised tomography study. British Journal of Psychiatry, 164, 16–26.CrossRefGoogle ScholarPubMed
Seeman, P., Bzowaj, N. H., Guan, H. C., et al (1987) Human brain D1 and D2 dopamine receptors in schizophrenia, Alzheimer's. Parkinson's and Huntington's diseases. Neuropsychopharmacology, 1, 5–15.CrossRefGoogle ScholarPubMed
Weinberger, D. R., Barman, K. F. & Illowsky, B. P. (1988) Physiological dysfunction of dorsolateral prefrontal cortex in schizophrenia. III. A new cohort and evidence for a monoaminergic mechanism. Archives of General Psychiatry, 45, 609–615.CrossRefGoogle Scholar
Wolfe, N., Katz, D. I., Albart, M. L., et al (1990) Neuropsychological profile linked to low dopamine in Alzheimer's disease, major depression, and Parkinson's disease. Journal of Neurosurgery and Psychiatry, 53, 915–917.CrossRefGoogle ScholarPubMed
Wong, D. F., Wagner, H. N., Tune, L. E., et al (1986) Positron emission tomography reveals elevated D2 dopamine receptors in drug naïve schizophrenics. Science, 244, 1558–1563.CrossRefGoogle Scholar
Wyatt, R. J. (1993) Practical Psychiatric Practice: Clinical Interview Forms. Rating Scales and Patient Handouts. Washington, DC: American Psychiatric Association.Google Scholar
Submit a response

eLetters

No eLetters have been published for this article.